PDBsum entry 4wbo

Transferase/transferase inhibitor

PDB id: 4wbo

Contents

Protein chains

497 a.a.

Ligands

ANW ×4

Metals

_CL ×4

Waters ×54

PDB id:

4wbo

Name:

Transferase/transferase inhibitor

Title:

Bovine g protein coupled receptor kinase 1 in complex with amlexanox

Structure:

Rhodopsin kinase. Chain: a, b, c, d. Synonym: rk,g protein-coupled receptor kinase 1. Engineered: yes

Source:

Bos taurus. Bovine. Organism_taxid: 9913. Gene: grk1, rhok. Expressed in: trichoplusia ni. Expression_system_taxid: 7111.

Resolution:

2.81Å R-factor: 0.243 R-free: 0.267

Authors:

K.T.Homan,J.J.G.Tesmer

Key ref:

K.T.Homan et al. (2014). Identification and characterization of amlexanox as a G protein-coupled receptor kinase 5 inhibitor. Molecules, 19, 16937-16949. PubMed id: 25340299 DOI: 10.3390/molecules191016937

Date:

03-Sep-14 Release date: 05-Nov-14

Protein chains

P28327  (RK_BOVIN) -  Rhodopsin kinase GRK1 from Bos taurus

Seq: 561 a.a.

Struc: 497 a.a.

Enzyme reactions

• Enzyme class: E.C.2.7.11.14 - rhodopsin kinase.
• Reaction:
  1. L-seryl-[rhodopsin] + ATP = O-phospho-L-seryl-[rhodopsin] + ADP + H⁺
  2. L-threonyl-[rhodopsin] + ATP = O-phospho-L-threonyl-[rhodopsin] + ADP + H⁺

Molecule diagrams generated from .mol files obtained from the KEGG ftp site

reference

DOI no: 10.3390/molecules191016937

Molecules 19:16937-16949 (2014)

PubMed id: 25340299

Identification and characterization of amlexanox as a G protein-coupled receptor kinase 5 inhibitor.

K.T.Homan, E.Wu, A.Cannavo, W.J.Koch, J.J.Tesmer.

ABSTRACT

G protein-coupled receptor kinases (GRKs) have been implicated in human diseases ranging from heart failure to diabetes. Previous studies have identified several compounds that selectively inhibit GRK2, such as paroxetine and balanol. Far fewer selective inhibitors have been reported for GRK5, a target for the treatment of cardiac hypertrophy, and the mechanism of action of reported compounds is unknown. To identify novel scaffolds that selectively inhibit GRK5, a differential scanning fluorometry screen was used to probe a library of 4480 compounds. The best hit was amlexanox, an FDA-approved anti-inflammatory, anti-allergic immunomodulator. The crystal structure of amlexanox in complex with GRK1 demonstrates that its tricyclic aromatic ring system forms ATP-like interactions with the hinge of the kinase domain, which is likely similar to how this drug binds to IκB kinase ε (IKKε), another kinase known to be inhibited by this compound. Amlexanox was also able to inhibit myocyte enhancer factor 2 transcriptional activity in neonatal rat ventricular myocytes in a manner consistent with GRK5 inhibition. The GRK1 amlexanox structure thus serves as a springboard for the rational design of inhibitors with improved potency and selectivity for GRK5 and IKKε.